A prospective, open label, controlled, multicentre trial to assess the effect of an induction regimen of Neoral (R), Myfortic (R) and corticosteroids, followed by administration of Certican (R) together with withdrawal of Neoral (R) on inflammatory and cardiovascular markers in kidney transplant recipients.

Trial Profile

A prospective, open label, controlled, multicentre trial to assess the effect of an induction regimen of Neoral (R), Myfortic (R) and corticosteroids, followed by administration of Certican (R) together with withdrawal of Neoral (R) on inflammatory and cardiovascular markers in kidney transplant recipients.

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jun 2016

At a glance

  • Drugs Ciclosporin (Primary) ; Everolimus (Primary) ; Mycophenolate sodium (Primary) ; Prednisolone (Primary)
  • Indications Renal transplant rejection
  • Focus Pharmacodynamics
  • Acronyms REVIVE
  • Most Recent Events

    • 08 Jun 2016 Status changed from not yet recruiting to completed.
    • 17 Aug 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top